Vyne Therapeutics Inc.
13F holders, Q3 2025 (September 30)33holders −11
7new positions
18sold out
$0.34avg. 13F price*
At the end of Q3 2025, 33 institutions reported holding Vyne Therapeutics Inc. in their 13F filings, down 11 from Q2 2025. 7 opened new positions and 18 sold out. The largest holders were Baker Bros. Advisors LP ($285K), Acorn Capital Advisors, LLC ($199K) and Shay Capital LLC ($165K).
- Company
- Vyne Therapeutics Inc.
- CUSIP
- 92941V308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $562K |
| Exits | 18 | $9.6M |
All 13F filers, Q2 2025 → Q3 2025: 2,190,298 shares bought and 6,314,210 shares sold, net −4,123,912 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 33 holders
| Baker Bros. Advisors LP | 0.00% | New | 851,353 | $285K |
| Acorn Capital Advisors, LLC | 0.10% | Reduce -20.4% | 586,572 | $199K |
| Shay Capital LLC | 0.03% | New | 492,577 | $165K |
| Acadian Asset Management LLC | 0.00% | Add +1891.3% | 446,414 | $148K |
| Ikarian Capital, LLC | 0.02% | No change | 290,000 | $97K |
| Two Sigma Investments, LP | 0.00% | New | 220,788 | $74K |
| Vanguard Group Inc. | 0.00% | Reduce -61.6% | 190,383 | $64K |
| Jane Street Group, LLC | 0.00% | Add +17.9% | 147,120 | $49K |
| Geode Capital Management, LLC | 0.00% | Add +2.8% | 137,122 | $46K |
| Boothbay Fund Management, LLC | 0.00% | No change | 106,459 | $36K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 76,958 | $26K |
| Susquehanna International Group, LLP | 0.00% | Reduce -0.1% | 57,763 | $19K |
| Two Sigma Advisers, LP | 0.00% | New | 56,600 | $19K |
| Rangeley Capital, LLC | 0.02% | New | 50,000 | $17K |
| Corsair Capital Management, L.P. | 0.00% | Add +400.0% | 50,000 | $17K |
| BlackRock, Inc. | 0.00% | No change | 44,405 | $15K |
| Gsa Capital Partners LLP | 0.00% | Add +166.8% | 35,921 | $12K |
| Northern Trust Corp. | 0.00% | No change | 23,110 | $8K |
| Commonwealth Equity Services, LLC | 0.00% | No change | 18,298 | $6K |
| State Street Corp. | 0.00% | No change | 15,765 | $5K |
| Harvest Investment Services, LLC | 0.00% | Reduce -78.5% | 11,059 | $4K |
| UBS Group AG | 0.00% | New | 5,572 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +28.3% | 3,597 | $1K |
| Royal Bank of Canada | 0.00% | No change | 2,440 | $1K |
| Bank of America Corp. | 0.00% | Add +4.3% | 1,532 | $513 |
| Mb, Levis & Associates, LLC | 0.00% | No change | 1,041 | $349 |
| Morgan Stanley | 0.00% | Reduce -73.3% | 911 | $305 |
| JPMorgan Chase & Co. | 0.00% | No change | 146 | $49 |
| Wells Fargo & Company | 0.00% | No change | 65 | $22 |
| Truvestments Capital LLC | 0.00% | No change | 25 | $8 |
| NFSG Corp | 0.00% | New | 10 | $3 |
| Cwm, LLC | 0.00% | No change | 500 | $0 |
| Centerpoint Advisors, LLC | 0.00% | No change | 350 | $0 |
"% of holder's portfolio" is VYNE THERAPEUTICS INC's weight in each manager's 13F, not the share of Vyne Therapeutics Inc. the manager owns.